Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-131-1095 plus enzalutamide in metastatic castration-resistant prostate cancer
NCT03939689Phase 2Completed
- Sponsor
- Progenics Pharmaceuticals
- Start
- May 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of mip-1095 i-131 in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Progenics Pharmaceuticals. Primary endpoint: Prostate-Specific Antigen Response Rate at 53 weeks. Started May 2019; status: completed.
02
Drugs
mip-1095 i-131
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03939689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939689.